The Experts below are selected from a list of 126 Experts worldwide ranked by ideXlab platform
Robert L Phyliky - One of the best experts on this subject based on the ideXlab platform.
-
true Malignant Histiocytosis
Mayo Clinic Proceedings, 1998Co-Authors: Wichean Mongkonsritragoon, Chinyang Li, Robert L PhylikyAbstract:Objective To attempt to distinguish cases of true Malignant Histiocytosis from the clinical syndromes of so called Malignant Histiocytosis with use of recent methods. Design We retrospectively studied the laboratory data and clinical course of Mayo patients who had clinical syndromes of so-called Malignant Histiocytosis and reviewed available paraffin-embedded tissue specimens to identify the nature of the Malignant cells. Material and Methods After elimination of cases of infection-associated hemophagocytic syndrome, we reviewed and studied seven cases of so-called Malignant Histiocytosis in patients who had undergone assessment at Mayo Clinic Rochester between 1973 and 1993 We identified histiocytes by using current morphologic, cytochemical, and immunohistochemical methods. The clonal nature of the Malignant cells was identified with morphologic, cytogenetic, and molecular genetic studies. Results Only one of the seven cases had a true histiocytic origin. The Malignant cells were T cells in three other cases (the cells were also CD30 + in two cases), CD30 + cells only in one case, epithelial cells in one case, and an undetermined cell type (stained positively only with antitrypsin) in one case. Conclusion True Malignant Histiocytosis is an exceedingly rare disease, and only a few reports have clearly identified the histiocytic origin of the Malignant cells. Previously, the lack of monoclonal antibodies specific to histiocytes and the absence of techniques for performing molecular genetic studies on paraffin-embedded tissue prevented the study of such cases. With newer techniques, cases of true Malignant Histiocytosis can now be identified.
Toshikuni Takano - One of the best experts on this subject based on the ideXlab platform.
-
true Malignant Histiocytosis developed during chemotherapy for mediastinal immature teratoma
Human Pathology, 1996Co-Authors: Shunichi Sasou, Shinichi Nakamura, Wataru Habano, Toshikuni TakanoAbstract:We report an autopsy case of true Malignant Histiocytosis that developed during chemotherapy for mediastinal immature teratoma. The patient was a 14-year-old boy who exhibited hepatosplenomegaly while receiving chemotherapy for a mediastinal immature teratoma that had been resected 11 months before. The spleen and liver of the excisional biopsy displayed infiltration of multinucleated giant atypical cells with prominent erythrophagia in massive aggregations. These atypical cells expressed CD68, α1-antitrypsin, α1-antichymotrypsin, lysozyme, and vimentin, suggesting that the tumor cells may have been derived from macrophages. Immunocytochemistry showed p53 expression in the tumor cells of the Malignant Histiocytosis, as well as in the elements of the immature teratoma. Direct sequence analysis showed the p53 mutation in the tumor cells of the immature teratoma to be a mutation at codon 175 (exon 5), whereas the mutation in the Malignant Histiocytosis occurred at codon 285 (exon 8), ie, polyclonality was exhibited and these features suggested that the Malignant Histiocytosis arose independently from the immature teratoma during the chemotherapy.
Wichean Mongkonsritragoon - One of the best experts on this subject based on the ideXlab platform.
-
true Malignant Histiocytosis
Mayo Clinic Proceedings, 1998Co-Authors: Wichean Mongkonsritragoon, Chinyang Li, Robert L PhylikyAbstract:Objective To attempt to distinguish cases of true Malignant Histiocytosis from the clinical syndromes of so called Malignant Histiocytosis with use of recent methods. Design We retrospectively studied the laboratory data and clinical course of Mayo patients who had clinical syndromes of so-called Malignant Histiocytosis and reviewed available paraffin-embedded tissue specimens to identify the nature of the Malignant cells. Material and Methods After elimination of cases of infection-associated hemophagocytic syndrome, we reviewed and studied seven cases of so-called Malignant Histiocytosis in patients who had undergone assessment at Mayo Clinic Rochester between 1973 and 1993 We identified histiocytes by using current morphologic, cytochemical, and immunohistochemical methods. The clonal nature of the Malignant cells was identified with morphologic, cytogenetic, and molecular genetic studies. Results Only one of the seven cases had a true histiocytic origin. The Malignant cells were T cells in three other cases (the cells were also CD30 + in two cases), CD30 + cells only in one case, epithelial cells in one case, and an undetermined cell type (stained positively only with antitrypsin) in one case. Conclusion True Malignant Histiocytosis is an exceedingly rare disease, and only a few reports have clearly identified the histiocytic origin of the Malignant cells. Previously, the lack of monoclonal antibodies specific to histiocytes and the absence of techniques for performing molecular genetic studies on paraffin-embedded tissue prevented the study of such cases. With newer techniques, cases of true Malignant Histiocytosis can now be identified.
Chinyang Li - One of the best experts on this subject based on the ideXlab platform.
-
true Malignant Histiocytosis
Mayo Clinic Proceedings, 1998Co-Authors: Wichean Mongkonsritragoon, Chinyang Li, Robert L PhylikyAbstract:Objective To attempt to distinguish cases of true Malignant Histiocytosis from the clinical syndromes of so called Malignant Histiocytosis with use of recent methods. Design We retrospectively studied the laboratory data and clinical course of Mayo patients who had clinical syndromes of so-called Malignant Histiocytosis and reviewed available paraffin-embedded tissue specimens to identify the nature of the Malignant cells. Material and Methods After elimination of cases of infection-associated hemophagocytic syndrome, we reviewed and studied seven cases of so-called Malignant Histiocytosis in patients who had undergone assessment at Mayo Clinic Rochester between 1973 and 1993 We identified histiocytes by using current morphologic, cytochemical, and immunohistochemical methods. The clonal nature of the Malignant cells was identified with morphologic, cytogenetic, and molecular genetic studies. Results Only one of the seven cases had a true histiocytic origin. The Malignant cells were T cells in three other cases (the cells were also CD30 + in two cases), CD30 + cells only in one case, epithelial cells in one case, and an undetermined cell type (stained positively only with antitrypsin) in one case. Conclusion True Malignant Histiocytosis is an exceedingly rare disease, and only a few reports have clearly identified the histiocytic origin of the Malignant cells. Previously, the lack of monoclonal antibodies specific to histiocytes and the absence of techniques for performing molecular genetic studies on paraffin-embedded tissue prevented the study of such cases. With newer techniques, cases of true Malignant Histiocytosis can now be identified.
Shunichi Sasou - One of the best experts on this subject based on the ideXlab platform.
-
true Malignant Histiocytosis developed during chemotherapy for mediastinal immature teratoma
Human Pathology, 1996Co-Authors: Shunichi Sasou, Shinichi Nakamura, Wataru Habano, Toshikuni TakanoAbstract:We report an autopsy case of true Malignant Histiocytosis that developed during chemotherapy for mediastinal immature teratoma. The patient was a 14-year-old boy who exhibited hepatosplenomegaly while receiving chemotherapy for a mediastinal immature teratoma that had been resected 11 months before. The spleen and liver of the excisional biopsy displayed infiltration of multinucleated giant atypical cells with prominent erythrophagia in massive aggregations. These atypical cells expressed CD68, α1-antitrypsin, α1-antichymotrypsin, lysozyme, and vimentin, suggesting that the tumor cells may have been derived from macrophages. Immunocytochemistry showed p53 expression in the tumor cells of the Malignant Histiocytosis, as well as in the elements of the immature teratoma. Direct sequence analysis showed the p53 mutation in the tumor cells of the immature teratoma to be a mutation at codon 175 (exon 5), whereas the mutation in the Malignant Histiocytosis occurred at codon 285 (exon 8), ie, polyclonality was exhibited and these features suggested that the Malignant Histiocytosis arose independently from the immature teratoma during the chemotherapy.